Trial Profile
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Inflammatory breast cancer
- Focus Therapeutic Use
- 08 Jul 2020 Planned End Date changed from 31 Jul 2023 to 1 Jun 2027.
- 08 Jul 2020 Planned primary completion date changed from 31 Jul 2023 to 1 Jun 2027.
- 16 Oct 2018 Status changed from not yet recruiting to recruiting.